脊髓性肌萎缩是由SMN1基因突变引起的遗传神经肌肉疾病，导致生存运动神经元蛋白不足，进行性运动神经元丧失和肌肉萎缩。干细胞研究探索神经源性细胞以支持或替代运动神经元，以及胎盘间充质干细胞分泌神经保护因子并减少神经炎症。由于SMA是遗传性疾病，不纠正基础SMN缺陷的细胞方法可能提供有限的长期获益。这将SMA与获得性疾病区别开来，并有助于解释为什么经批准的基因靶向疗法主导治疗。试验非常有限；报告的结果关注运动功能稳定化而非恢复。
五项注册试验和1项招募研究解决SMA中的干细胞疗法——这是此处条件中最小的景观。已发表数据稀少，主要为单中心观察性。某些描述6-12个月内的稳定化或缓慢下降；其他则变化最小。SMA的快速自然进展使任何稳定化可能引人注目，但在没有对照的情况下区分干细胞效应与已批准的疾病修饰疗法（nusinersen、基因疗法）很困难。没有试验逆转了运动神经元丧失。
指示性成本（如提供）大约为€4,500–€7,500/疗程——鉴于证据稀少，可获得性有限。作为参考，已批准的SMA疾病修饰疗法极其昂贵但保险覆盖且证，这设置了高标准：干细胞方法需要匹配其获益以正当自费成本。该数字仅供参考。
Cell therapy for Spinal Muscular Atrophy is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently 研究性. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Spinal Muscular Atrophy programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估